dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-12-11T17:30:29Z
dc.date.available2018-12-11T17:30:29Z
dc.date.created2018-12-11T17:30:29Z
dc.date.issued2017-01-01
dc.identifierJournal of Craniofacial Surgery, v. 28, n. 1, p. 227-230, 2017.
dc.identifier1536-3732
dc.identifier1049-2275
dc.identifierhttp://hdl.handle.net/11449/178469
dc.identifier10.1097/SCS.0000000000003291
dc.identifier2-s2.0-85004028211
dc.identifier8492596401380580
dc.description.abstractThis paper describes 3 patients of off-label use of bone morphogenetic protein 2 (rhBMP-2) in the reconstruction of mandibular continuity defects. In the first patient, rhBMP-2 was associated with iliac crest bone graft for late mandibular reconstruction after resection of osteosarcoma. In the 2 other patients, rhBMP-2 was used alone. In 1 patient the mandibular continuity defect was due to resection for treatment of osteomyelitis and in the other patient a continuity defect was created by unsuccessful osteogenic distraction for correction of mandibular hypoplasia. Despite the good results in those patients, the off-label use of rhBMP-2 is associated with increased rate of complications, so more studies are needed to assess the predictability of the use of rhBMP-2 in mandibular continuity defects. Therefore, at the moment the offlabel use of rhBMP-2 should be restricted to complicated bone defects in which the conventional alternatives of reconstruction were unsuccessful.
dc.languageeng
dc.relationJournal of Craniofacial Surgery
dc.relation0,448
dc.relation0,448
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectBone morphogenetic protein 2 (rhBMP-2)
dc.subjectBone regeneration
dc.subjectBone repair
dc.subjectMandibular continuity defect
dc.titleOff-label use of bone morphogenetic protein 2 in the reconstructions of mandibular continuity defects
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución